As EZH2 is also overexpressed in T-cell leukemia and lymphomas, its inhibition is of interest in these entities and the effective but limited reduction in cell viability as single therapy was proven repeatedly but could not be validated in the current study [4,19]. This evidence concerns the gene EZH2 and lymphoma.